Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925932 | 0.80 | GABRP (0.41) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL4598273 | 0.77 | IDO1 (0.47) | — | |
| SCHEMBL31508335 | 0.77 | CYP11B1 (0.41) | CHRNB2CHRNA4PARP1CYP11B1 | |
| SCHEMBL1391640 | 0.74 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL17064848 | 0.71 | CYP11B1 (0.37) | PARP1CYP11B1 | |
| SCHEMBL1171911 | 0.71 | CYP11B1 (0.37) | CHRNB2CHRNA4PARP1CYP11B1 | |
| SCHEMBL28037393 | 0.71 | CARM1 (0.44) | CHRM2CHRM1CHRM3 | |
| SCHEMBL29545943 | 0.71 | CYP11B1 (0.42) | CHRNB2CHRNA4PARP1CYP11B1 | |
| SCHEMBL11248120 | 0.71 | IDO1 (0.45) | — | |
| SCHEMBL744790 | 0.71 | CYP11B1 (0.42) | CHRNB2CHRNA4PARP1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | CHRM2 3375/4885CHRM1 4061/4885CHRM3 3310/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | CHRM2 3375/4885CHRM1 4061/4885CHRM3 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.